Substance / Medication

Tinzaparin

Overview

Active Ingredient
tinzaparin
RxNorm CUI
69646

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

15 trials linked to this intervention

15
Total Trials
4
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis.
Martínez-Zapata M José, Mathioudakis Alexander G, Mousa Shaker A et al. · Clin Appl Thromb Hemost · 2018
PMID: 28288527Meta-AnalysisFull text (PMC)
Tinzaparin for the treatment of foetal growth retardation: An open-labelled randomized clinical trial.
Hansen Anette Tarp, Sandager Puk, Ramsing Mette et al. · Thromb Res · 2018
PMID: 30114561RCT
Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial.
Qari Mohamad Hasan, Aljaouni Soad Khalil, Alardawi Mohamad Salleh et al. · Thromb Haemost · 2007
PMID: 17721622RCT
Sex differences in quality of life in stroke survivors: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST).
Gray Laura J, Sprigg Nikola, Bath Philip M W et al. · Stroke · 2007
PMID: 17901387RCT
Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss.
Dendrinos S, Kalogirou I, Makrakis E et al. · Clin Exp Obstet Gynecol · 2007
PMID: 17937086RCT
Tinzaparin, an alternative to subcutaneous unfractionated heparin, in patients with severe and end-stage renal impairment: a retrospective observational single-center study.
Gouin-Thibault Isabelle, Mansour Alexandre, Caribotti Charlène et al. · J Thromb Haemost · 2024
PMID: 39019439Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tinzaparin (substance)
SNOMED CT
412608008
UMLS CUI
C0216278
RxNorm CUI
69646

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
15
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.